Emotra’s Board of Directors has decided the following dates for release of financial reports and the annual shareholder meeting   161128-emotra-nyhetsbrev-dates-for-financial-reports-en

The European Commission has rejected Emotra’s application for approximately 3 MEUR, which we intended to use for three purposes: First of all to finance EUDOR-Y, a clinical multi-centre study on young people, secondly to develop EDOR® Interconnect, and thirdly to...

Last week in Chicago, Lars-Håkan Thorell, the inventor of EDOR® and the Company’s Head of research, held a presentation that gathered a great deal of attention. He presented the result of his research and how it led to the development of EDOR®....

The Board of Directors and the CEO of Emotra AB (publ) hereby present the interim report for the first nine months of the financial year 2016. 161026-interim-report-jan-sept-2016

This past week Lars-Håkan Thorell, the inventor of EDOR® and Emotra’s Head of research, has received a great deal of attention for his many years of research into identifying patients who are at risk of committing suicide. Thorell has been voted in as a member of the...

During the past few days, on September 8–11, Emotra participated in the 16th European Symposium on Suicide and Suicidal Behaviour, ESSSB, in Oviedo, Spain. New, exciting studies on EDOR® were presented by research groups from Oviedo and Novara.  ...

The article was published on the business news site Privataaffärer.se. We have translated the article and inserted it below. Direct link to the article: http://www.investerarbrevet.se/pages/1947 New ventures in the fight against suicide...

During the next few days, on September 8–11, Emotra will be participating in the 16th European Symposium on Suicide and Suicidal Behaviour, ESSSB, in Oviedo, Spain. EDOR® will be presented in different contexts during the conference and a special workshop about the...

160824 - Interim report Jan-June 2016

160804- Emotra - Newsletter - Comments on baseline PM-en